iQ-007 Zebrafish Screening Reveals Positive Results in Other Neurodegenerative Diseases
Princeton, NJ, June 21 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech company dedicated to the development of new epilepsy...
top of page
News
Search
Mar 19
Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study
Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel...
Jan 23
iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic Pain
Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel...
Nov 28, 2023
iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing
Princeton, NJ, 28 November, 2023 ─ iQure Pharma Inc, (iQure) a trailblazing pre-clinical drug discovery company focusing on central...
Oct 11, 2023
iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital
Princeton, NJ, October 11, 2023 ─ iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain...
Sep 5, 2023
iQ-007 Accepted into Prestigious NIH Preclinical Screening Platform for Pain (PSPP) Program
Princeton, NJ, September 5, 2023 ─ iQure Pharma Inc. (iQure), a company dedicated to the development of new epilepsy and pain management...
Aug 21, 2023
iQure Pharma’s iQ-007 Completes Critical Go/No Go Criteria - September Start for MTD & GLP Tox Study
Princeton, NJ, August 21, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has completed its key go/no go criteria enabling...
Jul 5, 2023
iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy
Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for...
May 15, 2023
iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone
Princeton, NJ, May 15, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved a major milestone by completing...
Feb 24, 2023
iQure Pharma’s iQ-007 & iQ-008 Compounds Continue to Deliver Promising Results
Princeton, NJ, February 24, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, is making significant progress in the...
Nov 15, 2022
iQ-007 shows no abuse potential in FDA recommended panel of tests
Princeton, NJ, November 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings...
Sep 18, 2022
iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track
iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to...
Sep 8, 2022
iQ-007 Considered as First-in-Class Therapeutic Agent in Prestigious Journal of Medicinal Chemistry
International team of scientists share research that demonstrates the effectiveness of iQ-007 and its unique mechanism of action...
Mar 15, 2022
iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Neuropathic Pain
DELAWARE, March 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings that...
Nov 5, 2021
Novel and promising mechanism of action for new neuropathic pain candidate iQ-007 confirmed
Delaware – November 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, can...
May 25, 2021
iQ-008 Accepted into NIH Preclinical Screening Platform for Pain (PSPP)
Delaware – May 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, is proud to...
Sep 22, 2020
Preliminary Subchronic Toxicology Study Results Indicate iQ-007 Has Favorable Safety Profile
Delaware – September 2020.iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new...
Jan 23, 2020
iQ-007: Confirmation of Safety Profile and Second Indication by NINDS (US)
Delaware – January 2020, iQure Pharma Inc., a company dedicated to preclinical and early development of Oncology and Central Nervous...
JPM Week
No Abuse
bottom of page